Weil has been recognized for advising on two transactions named “Impact Deal of the Year” at the LMG Life Sciences Americas Awards 2024: Sanofi’s $2.2 billion acquisition of Inhibrix and Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical Inc.

Weil advised Sanofi in its approximately $2.2 billion acquisition of Inhibrx, Inc., a clinical-stage biopharmaceutical company, following the spin-off of non-INBRX-101 assets into a new publicly traded company. The merger adds potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to Sanofi’s pipeline. The Weil team that advised Sanofi was led by Corporate Department Chairman Michael J. Aiello, Technology & IP Transactions Co-Head Jeffrey Osterman, U.S. Privacy and Cybersecurity Head Olivia Greer and Antitrust partner John Scribner.

Weil advised Johnson & Johnson in its approximately $13.1 billion acquisition of Shockwave Medical, a leading, first-to-market provider of innovative intravascular lithotripsy technology for the treatment of calcified CAD and PAD. The transaction expands Johnson & Johnson MedTech’s cardiac health medical device business. The Weil team that advised Johnson & Johnson was led by U.S. Antitrust Co-Head Jeffrey Perry and Antitrust partner Kristin Sanford.

The annual LMG Life Sciences Americas Awards recognize the best work in the life sciences sector and are based on extensive industry research and input from attorneys in the market.